'Egfr' diaporamas de présentation

Egfr - PowerPoint PPT Presentation


Cáncer de pulmón no microcítico EGFR mutado: Optimización del manejo del paciente

Cáncer de pulmón no microcítico EGFR mutado: Optimización del manejo del paciente

Cáncer de pulmón no microcítico EGFR mutado: Optimización del manejo del paciente. Manuel Cobo Dols Oncologia Médica H Regional Universitario Málaga. IBIMA 12-4-2018. EGFR TKIs versus Chemotherapy. Ongoing Study: erlotinib + bevacizumab vs. erlotinib as first-line treatment.

By benjamin
(736 views)

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy. Glioblastoma: The Current State of Affairs. No Improvement With Temozolomide Dose Intensification or Treatment Prolongation. Treatment at Recurrence. Glioblastoma: Improving Outcomes.

By Jims
(389 views)

Novel and Emerging Therapeutic Strategies in the Management of Non-Small Cell Lung Cancer

Novel and Emerging Therapeutic Strategies in the Management of Non-Small Cell Lung Cancer

Novel and Emerging Therapeutic Strategies in the Management of Non-Small Cell Lung Cancer. Matthew Gubens , MD, MS Associate Professor, Thoracic Medical Oncology University of California, San Francisco San Francisco, California. Grand Rounds Program Steering Committee.

By joanna
(241 views)

Quels examens de biologie moléculaire prescrire et obtenir en 2011?

Quels examens de biologie moléculaire prescrire et obtenir en 2011?

Quels examens de biologie moléculaire prescrire et obtenir en 2011?. I Rouquette. Plateformes hospitalières de génétique moléculaire des cancers.

By dyan
(179 views)

Marcello Tiseo U.O. Oncologia Medica Azienda Ospedaliero-Universitaria di Parma

Marcello Tiseo U.O. Oncologia Medica Azienda Ospedaliero-Universitaria di Parma

EGFR e meccanismi di resistenza agli inibitori. Marcello Tiseo U.O. Oncologia Medica Azienda Ospedaliero-Universitaria di Parma. Mutazioni di EGFR e TKIs: punti fermi. Netto impatto dei trattamenti in OS: 2-3 anni 8 studi random di I linea vs CT

By gianna
(276 views)

Supervivencia global en pacientes con CNMP con afectación hepática según EGFR

Supervivencia global en pacientes con CNMP con afectación hepática según EGFR

Supervivencia global en pacientes con CNMP con afectación hepática según EGFR. EGFR mutado (n = 8) SG= not reached. EGFR wild type (n = 43) SG=13 mo. Total n = 51. p = 0.023 * HR: 0.208 (95% CI 0.047 - 0.921).

By tamera
(114 views)

Progression-Free Survival Times

Progression-Free Survival Times

Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial. 1.0. 1.0. 1.0. EGFR-FISH:

By ivy
(112 views)

Victor Cohen, MDCM, FRCPC Department of Oncology Segal Cancer Center

Victor Cohen, MDCM, FRCPC Department of Oncology Segal Cancer Center

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC). Victor Cohen, MDCM, FRCPC Department of Oncology Segal Cancer Center SMBD – Jewish General Hospital McGill University.

By caia
(192 views)

BR.21 Study Design

BR.21 Study Design

BR.21 Study Design. Stratified by: Centre PS, 0/1 vs 2/3 Response to prior Rx (CR/PR:SD:PD) Prior regimens, (1 vs 2) Prior platinum, (Yes vs no). Erlotinib * 150mg/day. R. * 2:1 Randomization. Placebo “150 mg” daily.

By fagan
(100 views)

The Continuation of Biologic Agents Beyond Progression: Does It Make Sense?

The Continuation of Biologic Agents Beyond Progression: Does It Make Sense?

The Continuation of Biologic Agents Beyond Progression: Does It Make Sense?. Axel Grothey Mayo Clinic College of Medicine Rochester, MN. Continuation of Chemotherapy Beyond Progression. FOLFOX  FOLFIRI Tournigand FOLFIRI  FOLFOX Tournigand LV5FU2  FOLFIRI FOCUS LV5FU2  FOLFOX FOCUS

By enya
(116 views)

Aiming at the Wrong Target? Discussion of Abstracts CRA3507 (Alberts) and 3508 (Goldberg)

Aiming at the Wrong Target? Discussion of Abstracts CRA3507 (Alberts) and 3508 (Goldberg)

Aiming at the Wrong Target? Discussion of Abstracts CRA3507 (Alberts) and 3508 (Goldberg). Louis M. Weiner, MD Lombardi Comprehensive Cancer Center Georgetown University Medical Center. Potential Conflicts Relevant to this Presentation. Consultant, Stock Options Merrimack Pharmaceuticals

By annot
(148 views)

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib. N Engl J Med. 2011 Mar 10;364(10):947-55. Presentor: CR 周益聖 Supervisor: Vs 顏厥全. 財團法人台灣癌症臨床研究發展基金會. Outline. Introduction of lung cancer EGFR in NSCLC Important clinical trials of TKI

By zlhna
(513 views)

A B C

A B C

A B C. IC 50 (µM) MCF-7 MLET5 U0126 10.0 (0.75) 8.9 (0.4) LY294002 3.3 (0.04) 0.67 (0.01) . Supplementary Figure 2. EGFR, MAPK and AKT levels and activities in MLET lines, and growth response to specific inhibitors.

By atara
(127 views)

Lorenza Landi Istituto Toscano Tumori, Ospedale Civile, Livorno

Lorenza Landi Istituto Toscano Tumori, Ospedale Civile, Livorno

Clinical Implications of Micro-RNA in Cancer. Lorenza Landi Istituto Toscano Tumori, Ospedale Civile, Livorno. Background. Anti-EGFR Mabs cetuximab and panitumumab - alone or combination with chemotherapy - demonstrated efficacy in KRAS wild type mCRC patients.

By shea
(295 views)

Promising Future Biomarkers For Colorectal Cancer: Focus on Targeted Therapies

Promising Future Biomarkers For Colorectal Cancer: Focus on Targeted Therapies

Promising Future Biomarkers For Colorectal Cancer: Focus on Targeted Therapies. Lee M. Ellis, MD Depts of Surgical Oncology and Cancer Biology UT MD Anderson Cancer Center Houston, Texas USA. A Few Definitions A “marker” is not a “marker” is not a “marker”. Prognostic marker

By keely
(274 views)

William Pao, MD, PhD Assistant Director, Personalized Cancer Medicine

William Pao, MD, PhD Assistant Director, Personalized Cancer Medicine

Genotype-Driven Lung Cancer Treatment AAAS-FDLI Colloquium on Personalized Medicine October 27, 2009. William Pao, MD, PhD Assistant Director, Personalized Cancer Medicine Vanderbilt-Ingram Cancer Center Nashville, TN. Disclosure Information.

By rashad
(164 views)

ERK Signaling

ERK Signaling

Ag. Integrins. TGR-CD3 Complex. CaCn. EGFR. N. SHC. C. GRB2. GRB2. PYK2. ZAP70. AC. RTK. SOS. SHC. EPAC. VHR. GTP. GTP. G b. G a. G g. SOS. SOS. PLC b. PLC g. LAT. Rap1. PKA. PAK. Src. FAK. MKP. FAK. KSR. Raf1. PKC. MP1. c-Raf. Rac. PI3K. PP1/ PP2. MNK1/2.

By myrrh
(100 views)

Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan

Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan

Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases. Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan National Cancer Center, Tokyo Japan. Purpose.

By tannar
(150 views)

Introduction to the Basics of Signal Transduction

Introduction to the Basics of Signal Transduction

Introduction to the Basics of Signal Transduction. Mauricio Lema Medellín, Colombia. … Porque algunos en la audiencia no hablan español. Y ellos también fueron invitados. Signal Transduction. Introduction / Definition Components of ST Selected pathways Some newer drug targets Cross-Talk

By oona
(128 views)

Objectives

Objectives

Biologic Targeting in RT Bill McBride Dept. Radiation Oncology David Geffen School Medicine UCLA, Los Angeles, Ca. wmcbride@mednet.ucla.edu. Objectives. Understand the relationship between molecular carcinogenesis and radiation response Know how to target receptor tyrosine kinases

By iorwen
(93 views)

View Egfr PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Egfr PowerPoint presentations. You can view or download Egfr presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.